Handelen Satsuma Pharmaceuticals, Inc. - STSA CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.06 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Satsuma Pharmaceuticals Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.04 |
Open* | 1.05 |
1-Jaarlijkse Verandering* | -69.48% |
Dagelijks bereik* | 1.03 - 1.05 |
52 wekelijks bereik | 0.59-8.08 |
Weekgemiddelde volume (10 dagen) | 784.96K |
Gemiddeld volume (3 maanden) | 22.14M |
Marktkapitalisatie | 34.81M |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 33.15M |
Omzet | N/A |
EPS | -2.00 |
Dividend (opbrengst %) | N/A |
Beta | 0.10 |
Volgende inkomsten datum | Aug 7, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Jun 1, 2023 | 1.04 | 0.02 | 1.96% | 1.02 | 1.05 | 1.02 |
May 31, 2023 | 1.02 | 0.01 | 0.99% | 1.01 | 1.03 | 1.01 |
May 30, 2023 | 1.03 | 0.00 | 0.00% | 1.03 | 1.03 | 1.02 |
May 26, 2023 | 1.04 | 0.02 | 1.96% | 1.02 | 1.04 | 1.02 |
May 25, 2023 | 1.05 | 0.03 | 2.94% | 1.02 | 1.05 | 1.02 |
May 24, 2023 | 1.04 | 0.03 | 2.97% | 1.01 | 1.04 | 1.00 |
May 23, 2023 | 1.02 | -0.01 | -0.97% | 1.03 | 1.04 | 1.01 |
May 22, 2023 | 1.04 | 0.02 | 1.96% | 1.02 | 1.04 | 1.02 |
May 19, 2023 | 1.04 | 0.01 | 0.97% | 1.03 | 1.04 | 1.02 |
May 18, 2023 | 1.03 | -0.01 | -0.96% | 1.04 | 1.05 | 1.02 |
May 17, 2023 | 1.03 | -0.01 | -0.96% | 1.04 | 1.04 | 1.02 |
May 16, 2023 | 1.04 | 0.01 | 0.97% | 1.03 | 1.05 | 1.03 |
May 15, 2023 | 1.04 | 0.00 | 0.00% | 1.04 | 1.04 | 1.03 |
May 12, 2023 | 1.03 | -0.01 | -0.96% | 1.04 | 1.06 | 1.03 |
May 11, 2023 | 1.05 | 0.01 | 0.96% | 1.04 | 1.06 | 1.04 |
May 10, 2023 | 1.05 | 0.02 | 1.94% | 1.03 | 1.05 | 1.03 |
May 9, 2023 | 1.04 | 0.00 | 0.00% | 1.04 | 1.05 | 1.03 |
May 8, 2023 | 1.05 | 0.02 | 1.94% | 1.03 | 1.05 | 1.03 |
May 5, 2023 | 1.04 | 0.01 | 0.97% | 1.03 | 1.05 | 1.03 |
May 4, 2023 | 1.03 | 0.01 | 0.98% | 1.02 | 1.04 | 1.02 |
Satsuma Pharmaceuticals, Inc. Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
Friday, June 2, 2023 | ||
Tijd (UTC) (UTC) 17:00 | Land US
| Evenement Satsuma Pharmaceuticals Inc Annual Shareholders Meeting Satsuma Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
Monday, August 7, 2023 | ||
Tijd (UTC) (UTC) 20:05 | Land US
| Evenement Q2 2023 Satsuma Pharmaceuticals Inc Earnings Release Q2 2023 Satsuma Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 1, 2023 | ||
Tijd (UTC) (UTC) 20:05 | Land US
| Evenement Q3 2023 Satsuma Pharmaceuticals Inc Earnings Release Q3 2023 Satsuma Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
Totale bedrijfskosten | 70.947 | 51.166 | 48.328 | 28.881 | 7.515 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 15.126 | 13.531 | 12.058 | 4.685 | 1.082 |
Onderzoek & Ontwikkeling | 44.092 | 37.635 | 36.27 | 24.196 | 6.433 |
Bedrijfsresultaat | -70.947 | -51.166 | -48.328 | -28.881 | -7.515 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.892 | -0.006 | 0.765 | 0.707 | -0.018 |
Overige, Netto | 0 | -0.001 | 0.187 | ||
Netto inkomen voor belastingen | -70.055 | -51.172 | -47.563 | -28.175 | -7.346 |
Netto inkomen na belastingen | -70.055 | -51.172 | -47.563 | -28.175 | -7.346 |
Netto inkomen voor extra. Posten | -70.055 | -51.172 | -47.563 | -28.175 | -7.346 |
Netto inkomen | -70.055 | -51.172 | -47.563 | -28.175 | -7.346 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -70.055 | -51.172 | -47.563 | -28.175 | -7.346 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -70.055 | -51.172 | -47.563 | -28.175 | -7.346 |
Verwaterd Netto Inkomen | -70.055 | -51.172 | -47.563 | -28.175 | -7.346 |
Verwaterd Gewogen Gemiddelde Aandelen | 32.025 | 29.1744 | 17.4057 | 17.382 | 16.0893 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.18751 | -1.754 | -2.73261 | -1.62093 | -0.45658 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Verwaterde Genormaliseerde Winst per Aandeel | -1.82127 | -1.754 | -2.73261 | -1.62093 | -0.45658 |
Ongebruikelijke uitgaven (inkomsten) | 11.729 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
Totale bedrijfskosten | 10.768 | 23.592 | 15.409 | 16.4 | 15.546 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 3.309 | 3.165 | 4.067 | 3.904 | 3.99 |
Onderzoek & Ontwikkeling | 7.459 | 8.698 | 11.342 | 12.496 | 11.556 |
Bedrijfsresultaat | -10.768 | -23.592 | -15.409 | -16.4 | -15.546 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.474 | 0.462 | 0.269 | 0.132 | 0.029 |
Netto inkomen voor belastingen | -10.294 | -23.13 | -15.14 | -16.268 | -15.517 |
Netto inkomen na belastingen | -10.294 | -23.13 | -15.14 | -16.268 | -15.517 |
Netto inkomen voor extra. Posten | -10.294 | -23.13 | -15.14 | -16.268 | -15.517 |
Netto inkomen | -10.294 | -23.13 | -15.14 | -16.268 | -15.517 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -10.294 | -23.13 | -15.14 | -16.268 | -15.517 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -10.294 | -23.13 | -15.14 | -16.268 | -15.517 |
Verwaterd Netto Inkomen | -10.294 | -23.13 | -15.14 | -16.268 | -15.517 |
Verwaterd Gewogen Gemiddelde Aandelen | 33.1525 | 33.143 | 31.855 | 31.5529 | 31.5456 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.3105 | -0.69788 | -0.47528 | -0.51558 | -0.49189 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | -0.34972 | -0.34399 | -0.47528 | -0.51558 | -0.49189 |
Ongebruikelijke uitgaven (inkomsten) | 11.729 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totaal vlottende activa | 54.809 | 99.848 | 73.786 | 114.744 | 5.404 |
Geldmiddelen en kortetermijnbeleggingen | 52.481 | 93.15 | 68.236 | 107.697 | 5.205 |
Geldmiddelen & Equivalenten | 16.429 | 15.835 | 36.326 | 22.755 | 5.205 |
Prepaid Expenses | 2.328 | 6.698 | 5.55 | 7.047 | 0.199 |
Total Assets | 54.939 | 109.832 | 81.033 | 126.276 | 6.381 |
Property/Plant/Equipment, Total - Net | 0.108 | 6.792 | 6.473 | 0.832 | 0.445 |
Property/Plant/Equipment, Total - Gross | 0.108 | 7.414 | 6.906 | 1.027 | 0.512 |
Accumulated Depreciation, Total | 0 | -0.622 | -0.433 | -0.195 | -0.067 |
Other Long Term Assets, Total | 0.022 | 0.572 | 0.774 | 0.497 | 0.532 |
Total Current Liabilities | 8.115 | 8.492 | 8.046 | 7.971 | 1.965 |
Accounts Payable | 1.911 | 1.469 | 3.381 | 4.282 | 0.327 |
Accrued Expenses | 6.204 | 5.943 | 2.675 | 1.71 | 1.49 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 1.08 | 1.99 | 1.979 | 0.141 |
Other Current Liabilities, Total | 0.007 | ||||
Total Liabilities | 8.115 | 8.492 | 9.097 | 10.941 | 6.865 |
Total Long Term Debt | 0 | 0 | 1.042 | 2.951 | 4.824 |
Long Term Debt | 0 | 1.042 | 2.951 | 4.824 | |
Other Liabilities, Total | 0 | 0.009 | 0.019 | 0.076 | |
Total Equity | 46.824 | 101.34 | 71.936 | 115.335 | -0.484 |
Redeemable Preferred Stock | 0 | 0 | 12.134 | ||
Preferred Stock - Non Redeemable, Net | -0.486 | ||||
Common Stock | 0.003 | 0.003 | 0.002 | 0.002 | 0.001 |
Additional Paid-In Capital | 258.642 | 243.115 | 162.469 | 158.317 | 2.693 |
Retained Earnings (Accumulated Deficit) | -211.791 | -141.736 | -90.564 | -43.001 | -14.826 |
Total Liabilities & Shareholders’ Equity | 54.939 | 109.832 | 81.033 | 126.276 | 6.381 |
Total Common Shares Outstanding | 33.1525 | 31.5456 | 17.437 | 17.382 | 16.1053 |
Korte Termijn Investeringen | 36.052 | 77.315 | 31.91 | 84.942 | |
Long Term Investments | 0 | 2.62 | 10.203 | ||
Other Equity, Total | -0.03 | -0.042 | 0.029 | 0.017 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totaal vlottende activa | 43.375 | 54.809 | 67.563 | 72.474 | 84.083 |
Geldmiddelen en kortetermijnbeleggingen | 41.37 | 52.481 | 64.436 | 68.063 | 78.512 |
Geldmiddelen & Equivalenten | 19.526 | 16.429 | 40.556 | 23.763 | 21.359 |
Korte Termijn Investeringen | 21.844 | 36.052 | 23.88 | 44.3 | 57.153 |
Prepaid Expenses | 2.005 | 2.328 | 3.127 | 4.411 | 5.571 |
Total Assets | 43.479 | 54.939 | 75.037 | 80.151 | 93.672 |
Property/Plant/Equipment, Total - Net | 0.082 | 0.108 | 6.923 | 7.112 | 6.983 |
Other Long Term Assets, Total | 0.022 | 0.022 | 0.551 | 0.565 | 0.521 |
Total Current Liabilities | 5.831 | 8.115 | 6.658 | 7.892 | 6.585 |
Accounts Payable | 0.874 | 1.911 | 1.94 | 1.627 | 1.799 |
Accrued Expenses | 4.957 | 6.204 | 4.718 | 6.265 | 4.203 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 0.583 | |
Total Liabilities | 5.831 | 8.115 | 6.658 | 7.962 | 6.689 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | |||||
Other Liabilities, Total | 0.07 | 0.104 | |||
Total Equity | 37.648 | 46.824 | 68.379 | 72.189 | 86.983 |
Common Stock | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
Additional Paid-In Capital | 259.735 | 258.642 | 257.1 | 245.814 | 244.354 |
Retained Earnings (Accumulated Deficit) | -222.085 | -211.791 | -188.661 | -173.521 | -157.253 |
Other Equity, Total | -0.005 | -0.03 | -0.063 | -0.107 | -0.121 |
Total Liabilities & Shareholders’ Equity | 43.479 | 54.939 | 75.037 | 80.151 | 93.672 |
Total Common Shares Outstanding | 33.1525 | 33.1525 | 33.1259 | 31.5875 | 31.5456 |
Long Term Investments | 0 | 0 | 0 | 2.085 | |
Redeemable Preferred Stock | 0 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | -70.055 | -51.172 | -47.563 | -28.175 | -7.346 |
Geldmiddelen uit Operationele Activiteiten | -51.516 | -42.997 | -42.327 | -29.637 | -6.981 |
Geldmiddelen uit Operationele Activiteiten | 0.51 | 0.393 | 0.239 | 0.141 | 0.057 |
Niet-Geldelijke Posten | 17.662 | 6.681 | 4.203 | 0.755 | 0.013 |
Cash Taxes Paid | 0 | -0.005 | 0 | 0.01 | 0.004 |
Contant Betaalde Rente | 0.014 | 0.126 | 0.259 | 0.347 | 0.034 |
Veranderingen in het Operationeel Kapitaal | 0.367 | 1.101 | 0.794 | -2.358 | 0.295 |
Geldmiddelen uit Investeringsactiviteiten | 43.371 | -50.777 | 57.999 | -95.876 | -0.402 |
Kapitaaluitgaven | -0.472 | -2.03 | -5.165 | -0.551 | -0.402 |
Geldmiddelen uit Financieringsactiviteiten | 8.739 | 73.283 | -2.101 | 143.063 | 10.93 |
Uitgifte (Aflossing) van aandelen, netto | 0.122 | 0.068 | 0.134 | 143.23 | 5.986 |
Uitgifte (Aflossing) van Schulden, Netto | -1.083 | -2 | -2 | -0.167 | 4.944 |
Nettowijziging in Geldmiddelen | 0.594 | -20.491 | 13.571 | 17.55 | 3.547 |
Overige Cash Flow investeringsposten, Totaal | 43.843 | -48.747 | 63.164 | -95.325 | |
Financiering van Cash Flow Posten | 9.7 | 75.215 | -0.235 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -10.294 | -70.055 | -46.925 | -31.785 | -15.517 |
Cash From Operating Activities | -11.385 | -51.516 | -39.422 | -26.003 | -14.317 |
Cash From Operating Activities | 0 | 0.51 | 0.334 | 0.19 | 0.092 |
Non-Cash Items | 0.881 | 17.662 | 4.588 | 3.005 | 1.532 |
Cash Interest Paid | 0 | 0.014 | 0.014 | 0.014 | 0.011 |
Changes in Working Capital | -1.972 | 0.367 | 2.581 | 2.587 | -0.424 |
Cash From Investing Activities | 14.482 | 43.371 | 55.421 | 34.909 | 20.341 |
Capital Expenditures | 0 | -0.472 | -0.335 | -0.335 | -0.024 |
Other Investing Cash Flow Items, Total | 14.482 | 43.843 | 55.756 | 35.244 | 20.365 |
Cash From Financing Activities | 0 | 8.739 | 8.722 | -0.978 | -0.5 |
Financing Cash Flow Items | 9.7 | 9.7 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 0.122 | 0.105 | 0.105 | 0 | |
Issuance (Retirement) of Debt, Net | 0 | -1.083 | -1.083 | -1.083 | -0.5 |
Net Change in Cash | 3.097 | 0.594 | 24.721 | 7.928 | 5.524 |
Cash Taxes Paid | 0 | 0 | 0 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
BML Capital Management LLC | Investment Advisor | 19.4254 | 6440000 | 0 | 2023-03-31 | MED |
RA Capital Management, LP | Hedge Fund | 17.8395 | 5914252 | 0 | 2023-04-16 | LOW |
Shin Nippon Biomedical Laboratories Ltd | Corporation | 8.4281 | 2794113 | 0 | 2023-04-16 | |
New Enterprise Associates (NEA) | Venture Capital | 6.9198 | 2294095 | -194492 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.7766 | 920517 | 0 | 2023-03-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 1.7227 | 571129 | 101911 | 2023-03-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.2498 | 414344 | 5236 | 2023-03-31 | LOW |
Lion Point Capital, L.P. | Hedge Fund | 0.9645 | 319742 | 319742 | 2023-03-31 | MED |
Kollins (John A) | Individual Investor | 0.9377 | 310869 | 0 | 2023-03-31 | |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.8297 | 275069 | 0 | 2023-03-31 | MED |
Nan Fung Group Holdings Ltd | Corporation | 0.5366 | 177900 | 0 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.4962 | 164500 | -89600 | 2023-03-31 | HIGH |
Leonard (Braden Michael) | Individual Investor | 0.4525 | 150000 | 150000 | 2022-11-21 | |
Ikarian Capital LLC | Hedge Fund | 0.4104 | 136059 | 0 | 2023-03-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.3873 | 128408 | 1421 | 2023-03-31 | LOW |
Bridgeway Capital Management, LLC | Investment Advisor | 0.3629 | 120300 | 50000 | 2023-03-31 | LOW |
Marquette Wealth Management | Investment Advisor | 0.2369 | 78551 | 0 | 2023-03-31 | LOW |
PenderFund Capital Management, Ltd. | Investment Advisor | 0.2262 | 75000 | 75000 | 2023-04-30 | MED |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1877 | 62236 | 0 | 2023-03-31 | LOW |
Signal Iduna Asset Management GmbH | Investment Advisor | 0.1508 | 50000 | 0 | 2023-03-31 | MED |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Satsuma Pharmaceuticals, Inc. Company profile
Over Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf in een klinische fase. De onderneming is bezig met de ontwikkeling van een therapeutisch product voor de acute behandeling van migraine. De productkandidaat van de Vennootschap, STS101 is een geneesmiddel-geneesmiddel combinatie van een droge-poeder formulering van dihydroergotamine mesylate (DHE), dat zelf wordt toegediend door een voorgevuld, single-use, nasaal toedieningsapparaat.
Industry: | Bio Therapeutic Drugs |
4819 Emperor Boulevard
Suite 340
DURHAM
NORTH CAROLINA 27703
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen